3 Steps

Sign in to view your progression
Learning objectives
  • Identify the preferred agents for prevention of cardioembolic stroke in patients with atrial fibrillation (AF)
  • Timing of prevention
  • NOACs with proven efficacy are at least equal to or better than warfarin, with less side effects
  • What are the competing rationales for early and late intervention
  • How Idarucizumab the humanized fab fragment specific for the dabigatran molecule can be used as an antidote to dabigitran
Novel oral anticoagulant management issues for the stroke clinician
Case studies
Evaluation & Certificate
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings